AP1 factor inactivation in the suprabasal epidermis causes increased epidermal hyperproliferation and hyperkeratosis but reduced carcinogen-dependent tumor formation.
Activator protein one (AP1) (jun/fos) factors comprise a family of transcriptional regulators (c-jun, junB, junD, c-fos, FosB, Fra-1 and Fra-2) that are key controllers of epidermal keratinocyte survival and differentiation, and are important drivers of cancer development. Understanding the role of these factors in epidermis is complicated by the fact that each member is expressed in defined cell layers during epidermal differentiation, and because AP1 factors regulate competing processes (that is, proliferation, apoptosis and differentiation). We have proposed that AP1 factors function differently in basal versus suprabasal epidermis. To test this, we inactivated suprabasal AP1 factor function in mouse epidermis by targeted expression of dominant-negative c-jun (TAM67), which inactivates function of all AP1 factors. This produces increased basal keratinocyte proliferation, delayed differentiation and extensive hyperkeratosis. These findings contrast with previous studies showing that basal layer AP1 factor inactivation does not perturb resting epidermis. It is interesting that in spite of extensive keratinocyte hyperproliferation, susceptibility to carcinogen-dependent tumor induction is markedly attenuated. These novel observations strongly suggest that AP1 factors have distinct roles in the basal versus suprabasal epidermis, confirm that AP1 factor function is required for normal terminal differentiation, and suggest that AP1 factors have a different role in normal epidermis versus cancer progression.
Rorke
E A
EA
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. erorke@SOM.umaryland.edu
Adhikary
G
G
Jans
R
R
Crish
J F
JF
Eckert
R L
RL
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000818:Animals; D001483:Base Sequence; D002273:Carcinogens / Q000633:toxicity*; D049109:Cell Proliferation; D017931:DNA Primers; D004817:Epidermis / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology*; D016133:Polymerase Chain Reaction; D012871:Skin Diseases / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity; D018808:Transcription Factor AP-1 / Q000378:metabolism*
D002273:Carcinogens; D017931:DNA Primers; D018808:Transcription Factor AP-1; D015127:9,10-Dimethyl-1,2-benzanthracene; D013755:Tetradecanoylphorbol Acetate
Physiol Rev. 1989 Oct;69(4):1316-46
2678169
Exp Dermatol. 2005 Jul;14(7):519-27
15946240
J Invest Dermatol. 2006 Feb;126(2):243-57
16418733
Curr Opin Cell Biol. 1997 Apr;9(2):240-6
9069263
Oncogene. 1994 Mar;9(3):791-9
8108121
Epithelial Cell Biol. 1994 Jul;3(3):96-101
7534576
Photodermatol. 1987 Jun;4(3):127-34
3317295
Cancer Res. 1985 Nov;45(11 Pt 2):5845-50
2414001
Vet Clin North Am Equine Pract. 2004 Aug;20(2):319-43, vi
15271426
Mol Carcinog. 2002 Jun;34(2):72-7
12112313
Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1080-7
15037572
J Biol Chem. 1995 May 26;270(21):12614-22
7759510
Expert Opin Investig Drugs. 1999 Apr;8(4):393-401
15992087
Exp Gerontol. 2000 Feb;35(1):53-62
10705039
Exp Dermatol. 1999 Feb;8(1):71-9
10206724
Oncogene. 1995 Dec 21;11(12):2681-7
8545126
Oncogene. 2002 Jan 24;21(5):738-47
11850802
J Invest Dermatol. 2004 Jul;123(1):13-22
15191537
J Invest Dermatol. 2003 May;120(5):823-8
12713588
Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3429-41
7693609
Differentiation. 1994 Sep;57(3):187-93
7527355
J Biol Chem. 1995 Jul 14;270(28):16483-6
7622446
Differentiation. 1993 Jul;53(3):191-200
8405770
Mol Cancer Res. 2003 Sep;1(11):848-54
14517347
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2257-61
2648396
Cancer Res. 2002 Jun 1;62(11):3044-7
12036911
EMBO J. 2000 Jun 15;19(12):2969-79
10856241
J Investig Dermatol Symp Proc. 2002 Dec;7(1):27-35
12518789
J Invest Dermatol. 2008 Mar;128(3):530-41
17882273
J Biol Chem. 1998 Sep 18;273(38):24387-95
9733728
J Clin Invest. 2001 Oct;108(7):991-9
11581300
Ann N Y Acad Sci. 1998 Jun 30;851:139-46
9668616
J Invest Dermatol. 2006 Apr;126(4):902-11
16439969
Mol Carcinog. 2006 Jan;45(1):1-9
16302268
J Investig Dermatol Symp Proc. 2002 Dec;7(1):36-40
12518790
J Biol Chem. 2002 Aug 30;277(35):31753-60
12080077
Nat Genet. 2002 Feb;30(2):158-66
11818961
Development. 2000 Nov;127(22):4937-48
11044407
J Invest Dermatol. 2006 Feb;126(2):305-14
16374477
Physiol Rev. 1997 Apr;77(2):397-424
9114819
Cancer Res. 2002 Mar 1;62(5):1343-8
11888903
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9827-32
10449779
J Invest Dermatol. 1983 Jul;81(1 Suppl):109s-15s
6190956
Nature. 2005 Sep 15;437(7057):369-75
16163348
J Biol Chem. 2003 Sep 5;278(36):34277-85
12810719
Cancer Res. 1987 Sep 1;47(17):4674-80
2441853
Adv Dermatol. 2000;16:159-83; discussion 184
11094627
EMBO J. 2000 May 2;19(9):2056-68
10790372
Genes Dev. 2000 Nov 1;14(21):2695-700
11069886
Cell. 1985 Mar;40(3):677-83
2578890
Nat Cell Biol. 2002 May;4(5):E131-6
11988758
Oncogene. 2001 Apr 30;20(19):2390-400
11402335
Mol Biol Rep. 1996;23(1):59-70
8983019
J Dermatol Sci. 2002 Nov;30(2):94-9
12413764
Biochem J. 1998 Apr 1;331 ( Pt 1):61-8
9512462
Exp Dermatol. 2001 Feb;10(1):45-54
11168579
J Dermatol. 2004 Apr;31(4):271-6
15187321
J Biol Chem. 1998 Nov 13;273(46):30460-5
9804813
J Invest Dermatol. 2000 Nov;115(5):788-94
11069615
Mol Cell Biol. 2004 Sep;24(18):8167-83
15340077
Cell Death Differ. 1996 Oct;3(4):373-83
17180107
J Invest Dermatol. 2004 Aug;123(2):313-8
15245431
Cancer Res. 2007 Mar 15;67(6):2430-8
17363560
J Invest Dermatol. 2001 Jul;117(1):1-2
11442743
Cancer Res. 2000 Nov 15;60(22):6332-8
11103794
J Invest Dermatol. 2005 Jan;124(1):212-20
15654976
Oncogene. 2001 Apr 30;20(19):2413-23
11402337
Cell. 1995 Sep 8;82(5):721-32
7545543
Genes Dev. 1993 Mar;7(3):479-90
8383624